Home/Filings/4/0001178913-25-002412
4//SEC Filing

Burshtein Gregory 4

Accession 0001178913-25-002412

CIK 0001638097other

Filed

Jul 17, 8:00 PM ET

Accepted

Jul 18, 4:35 PM ET

Size

8.0 KB

Accession

0001178913-25-002412

Insider Transaction Report

Form 4
Period: 2025-07-16
Burshtein Gregory
Chief of R&D
Transactions
  • Award

    Stock Option (right to buy)

    2025-07-16+200,000200,000 total
    Exercise: $2.28Exp: 2035-04-28Ordinary Shares, par value NIS 0.0000769 per share (200,000 underlying)
  • Award

    Ordinary Shares, par value NIS 0.0000769 per share

    2025-07-16+26,316101,442 total
Footnotes (2)
  • [F1]Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on April 28, 2025, subject to approval by the Company's shareholders, which was obtained on July 16, 2025. This grant was awarded to the Reporting Person in lieu of the Reporting Person's 2024 annual cash bonus. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on April 28, 2025.
  • [F2]This grant of options was approved by the Board on April 28, 2025, subject to approval by the Company's shareholders, which was obtained on July 16, 2025. The options vest over a three-year period that commenced on April 28, 2025, with a third of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining two-year period.

Documents

1 file

Issuer

Entera Bio Ltd.

CIK 0001638097

Entity typeother

Related Parties

1
  • filerCIK 0002026002

Filing Metadata

Form type
4
Filed
Jul 17, 8:00 PM ET
Accepted
Jul 18, 4:35 PM ET
Size
8.0 KB